Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BOLD Stock Forecast 2026-2027
$2.48
Current Price
$55.51M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to BOLD Price Targets
+61.3%
To High Target of $4.00
+61.3%
To Median Target of $4.00
+61.3%
To Low Target of $4.00
BOLD Price Momentum
+2.9%
1 Week Change
+73.4%
1 Month Change
+105.0%
1 Year Change
+106.7%
Year-to-Date Change
-11.1%
From 52W High of $2.79
+158.1%
From 52W Low of $0.96
📊 TOP ANALYST CALLS
Did BOLD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Audentes is one of their latest high-conviction picks.
Latest BOLD Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, BOLD has a neutral consensus with a median price target of $4.00 (ranging from $4.00 to $4.00). The overall analyst rating is Buy (6.0/10). Currently trading at $2.48, the median forecast implies a 61.3% upside. This outlook is supported by 0 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Mitchell S. Kapoor at HC Wainwright & Co., projecting a 61.3% upside. Conversely, the most conservative target is provided by Mitchell S. Kapoor at HC Wainwright & Co., suggesting a 61.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BOLD Analyst Ratings
0
Buy
1
Hold
0
Sell
BOLD Price Target Range
Low
$4.00
Average
$4.00
High
$4.00
Current: $2.48
Latest BOLD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BOLD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 11, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $4.00 |
| Jun 2, 2025 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| May 28, 2025 | Leerink Partners | Market Perform | Downgrade | $N/A | |
| Dec 13, 2024 | Guggenheim | Neutral | Downgrade | $N/A | |
| Apr 22, 2024 | Leerink Partners | Outperform | Initiates | $N/A | |
| Apr 22, 2024 | Guggenheim | Buy | Initiates | $N/A | |
| Apr 22, 2024 | Piper Sandler | Overweight | Initiates | $N/A | |
| Dec 9, 2019 | Evercore ISI Group | In-Line | Downgrade | $N/A | |
| Dec 6, 2019 | JP Morgan | Neutral | Downgrade | $N/A | |
| Dec 4, 2019 | Chardan Capital | Neutral | Downgrade | $60.00 | |
| Dec 4, 2019 | SVB Leerink | Market Perform | Downgrade | $N/A | |
| Dec 3, 2019 | Piper Sandler | Neutral | Downgrade | $60.00 | |
| Dec 3, 2019 | Baird | Neutral | Upgrade | $N/A | |
| Dec 3, 2019 | BMO Capital | Market Perform | Downgrade | $60.00 | |
| Dec 3, 2019 | Citigroup | Neutral | Upgrade | $60.00 | |
| Dec 3, 2019 | Guggenheim | Neutral | Downgrade | $N/A | |
| Dec 3, 2019 | HC Wainwright & Co. | Neutral | Downgrade | $60.00 | |
| Dec 3, 2019 | Piper Jaffray | Neutral | Downgrade | $N/A | |
| Dec 3, 2019 | Raymond James | Market Perform | Downgrade | $N/A | |
| Dec 3, 2019 | Wedbush | Neutral | Downgrade | $N/A |
Boundless Bio, Inc. (BOLD) Competitors
The following stocks are similar to Audentes based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Boundless Bio, Inc. (BOLD) Financial Data
Boundless Bio, Inc. has a market capitalization of $55.51M with a P/E ratio of 0.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -50.2%.
Valuation Metrics
Market Cap
$55.51M
Enterprise Value
$10.25M
P/E Ratio
0.2x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+166.7%
Current Ratio
9.9x
Debt/Equity
55.9x
ROE
-50.2%
ROA
-22.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Boundless Bio, Inc. (BOLD) Business Model
About Boundless Bio, Inc.
What They Do
Develops novel therapies for cancer treatment.
Business Model
Boundless Bio Inc. generates revenue through the development of precision medicines targeting extrachromosomal DNA (ecDNA) in cancer therapy. By focusing on oncogenic amplification-driven cancers, the company aims to create targeted solutions that improve patient outcomes, positioning itself within the lucrative biotechnology market.
Additional Information
The company is at the forefront of genetic research, impacting cancer therapeutics and contributing to advancements in precision medicine. Boundless Bio's innovative approach signifies a shift towards personalized cancer treatments, underscoring the importance of genomic research in healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
28
CEO
Mr. Zachary D. Hornby
Country
United States
IPO Year
N/A
Website
boundlessbio.comBoundless Bio, Inc. (BOLD) Latest News & Analysis
Latest News
Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders
16 days ago
Quick Summary
Insiders could gain significant financial advantages that are not accessible to regular shareholders, potentially impacting investor interests.
Why It Matters
Insider financial benefits can indicate potential misalignment of interests, affecting stock performance and investor confidence. This may signal risks or opportunities in the company's future.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
25 days ago
Quick Summary
Serapha Bio will operate as the combined entity, focusing on advancing its in vivo base editing program for Alpha-1 Antitrypsin Deficiency.
Why It Matters
Serapha Bio's focus on a promising in vivo base editing program for Alpha-1 Antitrypsin Deficiency suggests potential for significant advancements in treatment, impacting market perception and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Monteverde & Associates is investigating Boundless Bio, Inc. (NASDAQ: BOLD) regarding its merger with Serapha Bio. BOLD shareholders may hold about 3.7% of the new entity post-merger.
Why It Matters
The investigation into Boundless Bio's merger may impact shareholder value and perceptions of the company, influencing stock performance and investment decisions.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Halper Sadeh LLC is investigating the merger between Boundless Bio, Inc. (NASDAQ: BOLD) and Serapha Bio, Inc., where Boundless shareholders will own about 3.7% of the combined entity.
Why It Matters
The investigation into Boundless Bio's merger may signal potential risks or shareholder dissatisfaction, impacting stock performance and investor sentiment regarding the deal.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Boundless Bio (Nasdaq: BOLD) is enrolling patients in the KOMODO-1 trial for BBI-940. The company has $93 million in cash, funding operations through the expected clinical readout.
Why It Matters
The progress in the KOMODO-1 trial and substantial cash reserves indicate potential for positive clinical outcomes, which can drive stock performance and investor interest in Boundless Bio.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BBI-940, an oral selective kinesin degrader, is in Phase 1 clinical development as a potential first-in-class treatment for advanced or metastatic breast cancers.
Why It Matters
Positive Phase 1 results for BBI-940 could lead to a breakthrough cancer treatment, potentially boosting the company's stock value and attracting investor interest in biotech innovation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BOLD Stock
What is Boundless Bio, Inc.'s (BOLD) stock forecast for 2027?
Based on our analysis of 11 Wall Street analysts, Boundless Bio, Inc. (BOLD) has a median price target of $4.00. The highest price target is $4.00 and the lowest is $4.00.
Is BOLD stock a good investment in 2027?
According to current analyst ratings, BOLD has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.48. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BOLD stock?
Wall Street analysts predict BOLD stock could reach $4.00 in the next 12 months. This represents a 61.3% increase from the current price of $2.48. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Boundless Bio, Inc.'s business model?
Boundless Bio Inc. generates revenue through the development of precision medicines targeting extrachromosomal DNA (ecDNA) in cancer therapy. By focusing on oncogenic amplification-driven cancers, the company aims to create targeted solutions that improve patient outcomes, positioning itself within the lucrative biotechnology market.
What is the highest forecasted price for BOLD Boundless Bio, Inc.?
The highest price target for BOLD is $4.00 from Mitchell S. Kapoor at HC Wainwright & Co., which represents a 61.3% increase from the current price of $2.48.
What is the lowest forecasted price for BOLD Boundless Bio, Inc.?
The lowest price target for BOLD is $4.00 from Mitchell S. Kapoor at HC Wainwright & Co., which represents a 61.3% increase from the current price of $2.48.
What is the overall BOLD consensus from analysts for Boundless Bio, Inc.?
The overall analyst consensus for BOLD is neutral. Out of 11 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are BOLD stock price projections?
Stock price projections, including those for Boundless Bio, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:12 AM UTC